Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer
This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Title: | Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer |
Authors: | Furusawa, Jun Browse this author | Homma, Akihiro Browse this author →KAKEN DB | Onimaru, Rikiya Browse this author →KAKEN DB | Sakashita, Tomohiro Browse this author →KAKEN DB | Yoshida, Daisuke Browse this author | Hatakeyama, Hiromitsu Browse this author →KAKEN DB | Mizumachi, Takatsugu Browse this author →KAKEN DB | Kano, Satoshi Browse this author →KAKEN DB | Tsuchiya, Kazuhiko Browse this author →KAKEN DB | Yasuda, Koichi Browse this author →KAKEN DB | Shirato, Hiroki Browse this author →KAKEN DB | Fukuda, Satoshi Browse this author →KAKEN DB |
Keywords: | Head and neck cancer | Hypopharyngeal cancer | Intra-arterial | Chemotherapy | Radiotherapy |
Issue Date: | Dec-2015 |
Publisher: | Elsevier |
Journal Title: | Auris nasus larynx |
Volume: | 42 |
Issue: | 6 |
Start Page: | 443 |
End Page: | 448 |
Publisher DOI: | 10.1016/j.anl.2015.04.003 |
PMID: | 25933585 |
Abstract: | Objective: We retrospectively assessed the indications for superselective intra-arterial infusion of cisplatin with concomitant radiotherapy (RADPLAT) in patients with hypopharyngeal cancer (HPC). Methods: Between April 2000 and March 2013,41 previously untreated patients received superselective intra-arterial infusion of cisplatin (100-120 mg/m2 per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional radiotherapy (65-70 Gy). Results: During the median follow-up period of 5.5 years, a statistically significant difference in the 5-year overall survival was noted between patients with N0-1 (n = 14) and N2b-3 disease (n = 27). One-half of deaths were observed to be the result of distant metastasis. The 5-year local control and overall survival were significantly better in patients with unilateral than in those with bilateral primary tumors. All the patients with T4b disease (n = 3) died of disease within 2 years. Conclusion: Indications for RADPLAT in patients with HPC were defined as patients with unilateral tumors staged as T3-4a and N0-1. |
Rights: | © 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/63714 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc) 国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 本間 明宏
|